CTOs on the Move

Q2 Solutions

www.q2labsolutions.com

 
Q² Solutions, a Quintiles Quest joint venture Launched in 2015, Q² Solutions (pronounced Q-squared) is a leading global clinical trials laboratory services organization. We help biopharmaceutical, medical device and diagnostics customers improve human health through innovation that transforms science and data into actionable medical insights. Q² Solutions is a quality driven, responsive partner with strong global experience and deep scientific and medical expertise. The Q² Solutions joint venture was formed by Quintiles and Quest Diagnostics, combining the best of each parent organizations clinical trials laboratory services capabilities.
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Abrazo Health Care

Abrazo Health Care is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Abrazo Health Care is based in Phoenix, AZ. You can find more information on Abrazo Health Care at www.abrazohealth.com

B. Braun Group

B. Braun is a German medical and pharmaceutical device company, which currently has more than 63,000 employees globally, and offices and production facilities in more than 60 countries.

Hospice of Southern Maine

Calling Hospice of Southern Maine doesn`t mean you`re giving up, it means you`re taking charge. At Hospice of Southern Maine, our mission is to provide compassion, care and comfort through the end of life for patients with a terminal illnesses and their families. We care for patients where they are, whether at home, in a long-term care and assisted living center, or at Gosnell Memorial Hospice House, our 18-bed facility in Scarborough.

Visa Solutions Healthcare

Visa Solutions Healthcare is a healthcare division that connects partners with highly qualified international registered nurses and allied clinicians. They offer a Care for your Dream program to help nurses work in the U.S. and provide diagnostics so...

T3D Therapeutics

T3D Therapeutics` mission is to develop its lead drug product candidate, T3D-959, as a potential `First-in-Class`and `Best-in-Class` disease-modifying, breakthrough medicine for the treatment of Alzheimer`s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D=959 and has initiated pre-clinical studies in Huntington’s Disease models.